(RTTNews) - Medincell SA (MEDCL.PA) reported that new long-term safety data from the completed Phase 3 SOLARIS trial support the potential of Olanzapine LAI (TEV-749) as the first long-acting ...

We read with interest the Article by Mitsue Saito and colleagues.1 The study showed that adding 5 mg olanzapine after ...

Zyprexa addition to standard antiemetics significantly reduces RINV incidence and severity in abdominal/pelvic radiotherapy patients. The trial showed marked improvements in nausea, vomiting, anxiety, ...